BB Good human data, but mixed outcomes or surrogate markers. How we grade →RCT (phase 2b and phase 3) · 652 and 1,024 adults aged 65 and older
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
J Mannick, G Teo, P Bernardo, D Quinn, K Russell, L Klickstein et al. The Lancet Healthy Longevity. 2021.
- In plain language
- In the phase 3 trial, 16 winter weeks of the mTOR inhibitor RTB101 did not reduce symptomatic respiratory illness (26% vs 25%, odds ratio 1.07), although antiviral gene activity rose; phase 2b was positive only in a second prespecified analysis.
- Limits
- Funded by resTORbio, which made the drug, and the NIA; company employee authors held equity. Tests RTB101, not rapamycin.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Rapamycin and mTOR: strong mouse lifespan data, early human trials
- Source
- doi.org/10.1016/S2666-7568(21)00062-3 · PubMed 33977284 · Free full text
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.